Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 02, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On November 1, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 27,249 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on November 2, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Investor Verification Points
- Verify the total number of shares transferred (27,249) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the involvement of directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop as interested parties in the GSK Trust alongside other employees.
- Note that this filing does not contain financial performance data for the period.